ChiCTR2200065977 版本V1.1 版本创建时间2023/05/03 22:27:53 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200065977 

最近更新日期:

Date of Last Refreshed on:

2022-11-21 11:14:56 

注册时间:

Date of Registration:

2022-11-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

瑞马唑仑在无痛支气管镜诊疗中应用的研究

Public title:

Study on the application of remazolam in painless bronchoscopy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

瑞马唑仑在无痛支气管镜诊疗中应用的研究

Scientific title:

Study on the application of remazolam in painless bronchoscopy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘叶芬 

研究负责人:

贺亮 

Applicant:

Liu yefen 

Study leader:

He liang 

申请注册联系人电话:

Applicant telephone:

13795739661

研究负责人电话:

Study leader's
telephone:

18928961518

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2414208180@qq.com

研究负责人电子邮件:

Study leader's E-mail:

54061799@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

简阳市人民医院

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市天河区棠下街道枫叶路212号

研究负责人通讯地址:

广东省广州市从化区从城大道566号

Applicant address:

212 Maple Leaf Road, Tangxia Street, Tianhe District, Guangzhou City, Guangdong Province

Study leader's address:

566 Congcheng Dadao, Conghua District, Guangzhou City, Guangdong Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南方医科大学第五附属医院

Applicant's institution:

The Fifth Affiliated Hospital of Southern Medical University

研究负责人所在单位:

南方医科大学第五附属医院

Affiliation of the Leader:

566 Congcheng Dadao, Conghua District, Guangzhou City, Guangdong Province

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022-MZK-K-001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南方医科大学第五附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the Fifth Affiliated Hospital of Southern Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2022-07-19 00:00:00

伦理委员会联系人:

曾方银

Contact Name of the ethic committee:

Zeng Fangyin

伦理委员会联系地址:

广东省广州市从化区从城大道566号

Contact Address of the ethic committee:

566 Congcheng Dadao, Conghua District, Guangzhou, Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 18665000011

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南方医科大学第五附属医院

Primary sponsor:

The Fifth Affiliated Hospital of Southern Medical University

研究实施负责(组长)单位地址:

广东省广州市从化区从城大道566号

Primary sponsor's address:

566 Congcheng Dadao, Conghua District, Guangzhou City, Guangdong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

广州市

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

南方医科大学第五附属医院

具体地址:

从化区从城大道566号

Institution
hospital:

The Fifth Affiliated Hospital of Southern Medical

Address:

566 Congcheng Avenue, Conghua District

经费或物资来源:

中国红十字基金会医学赋能公益专项基金“医学赋能及人才培养计划”临床科研项目

Source(s) of funding:

Clinical research project of

研究疾病:

行支气管镜检查的患者  

Target disease:

Patients undergoing bronchoscopy

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探讨瑞马唑仑在纤之镜检查中的安全剂量以及对患者的术后认知功能影响  

Objectives of Study:

To investigate the safe dose of remazolam in fiberoptic examination and its effect on postoperative cognitive function

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

选取南方医科大学第五附属医院2022年9月-2024年8月进行纤支镜检查的120例患者,ASA分级为Ⅰ级-Ⅱ级,年龄18-70岁,所有患者都是自愿参与本研究,所有纳入者均签署知情同意书

Inclusion criteria

A total of 120 patients, ASA grade ⅰ-ⅱ, aged 18-70 years old, who underwent fiberoptic bronchoscopy in the Fifth Affiliated Hospital of Southern Medical University from September 2022 to August 2024 were selected. All patients voluntarily participated in this study, and all participants signed informed consent

排除标准:

(1)合并有严重的心律失常;(2)存在重要器官功能不全;(3)存在神经系统疾病;(4)存在药物过敏史。

Exclusion criteria:

Complicated with severe arrhythmia; There is vital organ insufficiency; The presence of neurological diseases; A history of drug allergy.

研究实施时间:

Study execute time:

From 2022-09-01 00:00:00 To 2024-08-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-12-01 00:00:00 To 2023-11-30 00:00:00

干预措施:

Interventions:

组别:

R1组

样本量:

30

Group:

R1 group

Sample size:

干预措施:

瑞马唑仑0.15mg/kg

干预措施代码:

Intervention:

Remazolam 0.15 mg/kg

Intervention code:

组别:

R2组

样本量:

30

Group:

R2 group

Sample size:

干预措施:

瑞马唑仑0.20mg/kg

干预措施代码:

Intervention:

Remazolam 0.20 mg/kg

Intervention code:

组别:

R3组

样本量:

30

Group:

R3 group

Sample size:

干预措施:

瑞马唑仑0.25mg/kg

干预措施代码:

Intervention:

Remazolam 0.25 mg/kg

Intervention code:

组别:

P组

样本量:

30

Group:

Group P

Sample size:

干预措施:

丙泊酚2mg/kg

干预措施代码:

Intervention:

Propofol 2 mg/kg

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广州市 

市(区县):

广州市 

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

南方医科大学第五附属医院 

单位级别:

三甲 

Institution
hospital:

The Fifth Affiliated Hospital of Southern Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

镇静效果

指标类型:

主要指标

Outcome:

Calm effect

Type:

Primary indicator

测量时间点:

术毕

测量方法:

Measure time point of outcome:

End of the surgery

Measure method:

指标中文名:

生命体征

指标类型:

次要指标

Outcome:

Vital signs

Type:

Secondary indicator

测量时间点:

术中

测量方法:

监护仪

Measure time point of outcome:

Intraoperative

Measure method:

Monitor

指标中文名:

认知功能

指标类型:

主要指标

Outcome:

Cognitive function

Type:

Primary indicator

测量时间点:

术后

测量方法:

改良警觉量表镇静评分

Measure time point of outcome:

postoperative

Measure method:

modified obsevers assessment of alertness/sedation scale, MOAA/S

指标中文名:

不良反应

指标类型:

次要指标

Outcome:

Adverse reactions

Type:

Secondary indicator

测量时间点:

术中

测量方法:

Measure time point of outcome:

intraoperative

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

no

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数表

Randomization Procedure (please state who generates the random number sequence and by what method):

Stochastic indicator

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

将不同剂量的瑞马唑仑和丙泊酚外包装标记为A、B、C、D,使其相互之间不能区别,但可区别于其它的药物,将每个受试者的所有药物分装入一个药袋,在药袋外编号(1.2,3,4……)

Blinding:

Different doses of rematazolam and propofol were labeled as A, B, C, and D on the outer packaging, so that they could not be distinguished from each other, but could be distinguished from other drugs. All drugs of each subject were separately packed into a medicine bag and numbered outside the bag (1.2, 3,4...). .

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

项目组根据研究进程择期选择具体方式公开原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

According to the research process, the project team will select a specific way to disclose the original data

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

研究者根据受试者的原始观察记录,将数据及时、完整、正确、清晰地载入病例报考表,录入采用相应的数据库系统双人双机录入,之后对数据库进行两遍比对。电子数据文件分类保存,并有多次备份保存于不同磁盘,妥善保存,防止损坏。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

According to the original observation records of the subjects, the data were timely, complete, correct and clear into the case registration form. The data were entered into the corresponding database system with two-person and two-machine input, and then the database was compared twice. Electronic data files are stored in different categories, and multiple backups are stored in different disks, and stored properly to prevent damage.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-11-21 11:14:25